Wegovy Pill vs Mounjaro Cost: UK Price Comparison Guide

Wegovy pill vs Mounjaro cost is a key consideration for anyone managing weight privately in the UK. The Wegovy pill (semaglutide) typically starts at around £70–£100 per month, while Mounjaro (tirzepatide) commonly begins at £140–£180 per month, making oral Wegovy the cheaper option at many dose levels. However, prices vary by provider, dose strength, and whether promotional rates apply. This article compares private UK costs across the full dose escalation schedules for both treatments, estimates realistic annual spending, and explains what to consider before switching medicines on cost grounds alone.

Wegovy Pill vs Mounjaro Cost: Which Is Cheaper in the UK?

The Wegovy pill is often cheaper than Mounjaro at UK private-market prices, broadly ranging from £70–£200 per month compared with £140–£375 or more for Mounjaro, though the exact difference depends on dose and provider.

When comparing Wegovy pill vs Mounjaro cost in the UK, the Wegovy pill will often have the lower private monthly price, particularly at the beginning of treatment and when compared with higher Mounjaro doses. However, there is no single price that applies to every pharmacy, and the cheapest option can change depending on dose, provider, promotions and what is included in the service.

As a broad current UK private-market guide:

• Wegovy pill: approximately £70–£200 or more per month

• Mounjaro: approximately £140–£375 or more per month

These ranges are intentionally broad. The lowest Wegovy pill prices may depend on introductory offers, subscriptions or other conditions. At many providers, a more typical standard starting price is around £90–£100 per month. Higher-strength oral Wegovy treatment may be advertised at approximately £180–£200 per month.

Mounjaro usually starts higher. Lower-dose private Mounjaro treatment commonly begins at roughly £140–£180 per month, although some providers charge more. As the dose increases, prices may rise toward £250–£300, and some providers charge £300–£375 or more for higher strengths.

This means that, purely on monthly private price, the Wegovy pill can be considerably cheaper than high-dose Mounjaro. However, patients should not assume that everyone taking Mounjaro will progress to the most expensive dose or that everyone taking oral Wegovy will remain at the cheapest starting strength.

The medicines also contain different active ingredients. The Wegovy pill contains semaglutide, a GLP-1 receptor agonist.^[6][7] Mounjaro contains tirzepatide, which acts at both GIP and GLP-1 receptors.^[4][9] They have different approved dosing schedules and cannot be compared milligram for milligram.

The standard Wegovy pill schedule is:

• 1.5 mg once daily as the starting dose

• 4 mg once daily after at least one month

• 9 mg once daily after at least one month at 4 mg

• 25 mg once daily as the standard maintenance dose

Mounjaro is injected once weekly. The adult schedule begins at:

• 2.5 mg once weekly for four weeks

• then 5 mg once weekly

• with further increases in 2.5 mg steps to 7.5 mg, 10 mg, 12.5 mg or 15 mg where clinically appropriate

Patients stay at each increased Mounjaro dose for at least four weeks before a further increase.^[1][5] Not everyone needs the maximum 15 mg dose.

The simplest answer is therefore that the Wegovy pill is often cheaper than Mounjaro at current UK private prices, especially compared with higher Mounjaro strengths, but the exact saving depends on the prescribed dose and provider.

How Wegovy Pill and Mounjaro Prices Change as the Dose Increases

Both medicines become more expensive at higher doses; Wegovy pill prices rise from around £70–£110 at 1.5 mg to £180–£200 at 25 mg, while Mounjaro rises from approximately £140–£210 at 2.5 mg to £270–£375 or more at 15 mg.

A fair Wegovy pill vs Mounjaro price comparison needs to account for dose escalation. Comparing only the cheapest starter prices can give a misleading impression of long-term affordability.

For the Wegovy pill, an illustrative private-market range might look like:

• 1.5 mg: approximately £70–£110 per month

• 4 mg: approximately £90–£125 per month

• 9 mg: approximately £115–£145 per month

• 25 mg: approximately £180–£200 or more per month

These are not fixed national prices. Some providers advertise lower introductory rates, while others charge more. Availability of individual strengths should also be checked because a provider may advertise a price for a strength that is available for pre-order or expected later rather than immediate dispatch.

For Mounjaro, broad private-market ranges might look like:

• 2.5 mg: approximately £140–£210 per month

• 5 mg: approximately £165–£240 per month

• 7.5 mg: approximately £215–£315 per month

• 10 mg: approximately £230–£340 per month

• 12.5 mg: approximately £255–£355 per month

• 15 mg: approximately £270–£375 or more per month

Again, these are broad market ranges rather than guaranteed prices. Some pharmacies are substantially cheaper than others, and discounts can temporarily move a provider below the normal market range.

The contrast becomes particularly noticeable at higher doses. A patient prescribed a 25 mg Wegovy tablet may see private prices around the high £100s per month, while someone prescribed 12.5 mg or 15 mg Mounjaro may face monthly prices approaching or exceeding £300.

However, this does not mean every Mounjaro patient will pay the upper-end figure. The recommended Mounjaro maintenance doses for adults include 5 mg, 10 mg and 15 mg once weekly, and dose increases are based on the treatment plan and clinical need.^[5][11] A patient doing well on 5 mg may remain at that dose rather than progressing automatically to 15 mg.

Similarly, oral Wegovy does not always progress mechanically regardless of tolerability. The standard schedule leads toward 25 mg, but current prescribing information allows treatment to remain at the previous dose level where needed.

Provider pricing models also affect the comparison. A pharmacy may use:

• introductory first-month offers

• discount codes

• subscription prices

• multi-month packages

• returning-patient rates

• different delivery charges

• bundled clinical support

A Wegovy pill advertised at £69 and Mounjaro advertised at £149 may therefore not remain £80 apart throughout treatment. The Wegovy offer could expire, while a Mounjaro provider could apply a discount at renewal.

Patients should compare the actual price of their likely treatment pathway rather than asking only which medicine has the lower starting price.

How Much Could Wegovy Pills and Mounjaro Cost Over a Year?

A full year of oral Wegovy treatment may cost roughly £1,900–£2,200, while Mounjaro could range from approximately £2,000 to over £4,000 annually, depending on the maintenance dose reached and the provider used.

The potential annual cost of Wegovy pills versus Mounjaro can differ substantially because the dose schedules and private prices are different. Any annual estimate should be treated as illustrative rather than a guaranteed treatment quote.

For oral Wegovy, a simplified example might use:

• Month 1 at 1.5 mg: approximately £70–£110

• Month 2 at 4 mg: approximately £90–£125

• Month 3 at 9 mg: approximately £115–£145

• Month 4 onward at 25 mg: approximately £180–£200 or more per month

Using those assumptions, a year of Wegovy pill treatment could cost roughly £1,900–£2,200 or more.

That estimate assumes progression through the standard dose schedule and approximately nine months at the 25 mg maintenance strength. Actual spending may be lower or higher if:

• the patient stays longer at a previous dose

• the provider charges outside the illustrative ranges

• an introductory discount applies

• prices change during the year

• treatment is stopped or interrupted

Mounjaro is more difficult to reduce to one annual figure because patients may remain on different maintenance doses. An illustrative patient who increases through several strengths may face something like:

• Month 1 at 2.5 mg: approximately £140–£210

• Month 2 at 5 mg: approximately £165–£240

• Later doses: potentially £215–£375 or more per month, depending on the prescribed strength and provider

A broad annual private cost could therefore range from approximately £2,000 to more than £4,000.

The lower end could apply to someone using a competitively priced provider and remaining on a lower maintenance dose. The upper end becomes more plausible for someone progressing to 12.5 mg or 15 mg at a more expensive private service.

For illustration, a patient who reaches 15 mg and pays around £300 per month for much of the year will naturally spend substantially more than someone who remains on 5 mg at under £200 per month.

This is why statements such as "Mounjaro costs £149 per month" can be misleading. £149 may describe a starting dose at one provider, not the cost of the patient's later prescribed strength.

The same issue applies to the Wegovy pill. A headline offer from £69 or £79 should not be multiplied by 12 and presented as a realistic annual treatment cost if the normal schedule moves through progressively priced strengths.

A more useful budgeting method is to ask:

1. What is the current price of my starting dose?
2. What will the next likely dose cost?
3. Which maintenance dose might be clinically appropriate?
4. What happens when promotional pricing ends?
5. Does the provider require a subscription?
6. Are consultation, aftercare and delivery included?

On current broad market ranges, oral Wegovy may offer a lower annual private cost than Mounjaro, particularly when compared with patients using higher Mounjaro strengths. But this is not guaranteed for every individual.

Should You Switch From Mounjaro to the Wegovy Pill to Save Money?

Switching from Mounjaro to the Wegovy pill requires a clinical review, as the two medicines contain different active substances with no universal dose-conversion table, and the daily fasting requirement for oral Wegovy must also be considered.

The cost difference may lead some patients to consider switching from Mounjaro to the Wegovy pill, particularly if they are paying several hundred pounds per month for a higher Mounjaro dose. However, a lower price does not create a direct or automatic switching pathway.

Mounjaro and Wegovy contain different medicines:

• Mounjaro contains tirzepatide

• Wegovy contains semaglutide

There is no universal UK conversion table showing that a particular Mounjaro dose equals a particular Wegovy pill dose. For example, a patient taking 15 mg Mounjaro should not assume they can automatically move to 25 mg oral Wegovy, and someone taking 5 mg Mounjaro should not calculate an equivalent tablet strength from the milligram numbers.

Current prescribing information also does not provide one universal waiting period that applies to every Mounjaro-to-Wegovy-pill switch. The transition should be planned using the patient's treatment history, current dose, side effects, other medicines and the timing of the final injection.

Price can still be a legitimate subject to discuss with a prescriber. A patient may reasonably say that their current treatment has become financially difficult to sustain and ask whether another clinically appropriate option is available. Cost matters because a treatment that cannot be afforded long term may be difficult to continue consistently.

However, the comparison should include more than medicine price.

Mounjaro is once weekly. A single KwikPen contains four weekly doses, providing approximately four weeks of treatment.^[8][17]

The Wegovy pill is taken once daily. It should be taken on an empty stomach after fasting for at least 8 hours, with a small amount of water, followed by at least 30 minutes before eating, drinking or taking other oral medicines.^[7][6]

This means a cheaper pill may not be the best practical choice for someone who cannot reliably follow the daily fasting routine. Conversely, someone with strong needle anxiety may value the tablet even where the saving is modest.

Patients should also avoid assuming that a cheaper medicine provides identical weight-loss results. Tirzepatide and semaglutide are different active substances. Results from separate clinical trials should not be treated as though the Wegovy pill and Mounjaro were directly compared in one simple head-to-head study under identical conditions.

Side effects are another consideration. Both treatments commonly cause gastrointestinal effects such as nausea, diarrhoea, constipation and vomiting.^[10][13] Switching to a tablet does not guarantee that these problems disappear.

A patient considering a switch should therefore ask:

• How much am I currently paying at my actual Mounjaro dose?

• What would the prescribed Wegovy pill dose cost?

• Is the lower advertised price only introductory?

• Can I follow the daily fasting instructions?

• What treatment response have I had on Mounjaro?

• Am I switching because of affordability, side effects, injections or several factors?

In summary, the Wegovy pill is often cheaper than Mounjaro at current UK private-market prices, with the largest potential difference seen against higher Mounjaro strengths. Oral Wegovy may start at around £70–£100 at the lower end of the market and rise toward approximately £180–£200 at higher strengths, while Mounjaro may start around £140–£180 and rise toward £300–£375 or more depending on dose and provider.

These figures are market ranges, not guaranteed prices. Patients should compare the ongoing cost of the dose they are actually prescribed, check promotion and subscription conditions, and seek a clinical review before changing treatment. The cheapest medicine on a price table is not automatically the most appropriate treatment for an individual.

Scientific References

1. Mounjaro KwikPen 2.5 mg solution for injection in pre-filled pen – Summary of Product Characteristics.
2. Wegovy 2.4 mg, FlexTouch solution for injection in pre-filled pen – Summary of Product Characteristics.
3. Wegovy – EPAR Product Information.
4. Mounjaro – EPAR Public Assessment Report.
5. Mounjaro – EPAR Product Information.
6. First oral GLP-1 treatment for weight management.
7. First GLP-1 tablet for weight loss approved in the UK.
8. Four-dose Mounjaro KwikPen approved by MHRA for diabetes and weight management.
9. GLP-1 medicines for weight loss and diabetes: what you need to know.
10. GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse.
11. Tirzepatide for managing overweight and obesity – Practical guide: prescribing, reviewing and stopping tirzepatide.
12. Semaglutide | Drugs – BNF – NICE.
13. Tirzepatide | Drugs – BNF – NICE.
14. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5).
15. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2).
16. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.
17. Mounjaro KwikPen 2.5 mg – Patient Information Leaflet.
18. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) – PubMed.

Frequently Asked Questions